AB-7000

About Arsenal Biosciences

Arsenal Biosciences is a private, clinical-stage biotechnology company founded in 2019 and headquartered in South San Francisco, California. The company is developing next-generation, programmable T cell therapies for solid tumors, leveraging a proprietary technology platform that integrates synthetic biology and computational tools. ArsenalBio has established a strategic multi-program collaboration with Bristol Myers Squibb and is advancing a wholly owned pipeline, with its lead candidate, AB-3028 for prostate cancer, anticipated to enter First-in-Human trials in the first half of 2026. The company is led by a seasoned team with deep expertise in cell therapy, oncology, and company building.

Therapeutic Areas